Developer docs
API playgroundTry for free, no card

Search company profiles

Ellipses Pharma

Full company profile

uuid0006wav

Namestring
Ellipses Pharma
Legal namestring
Ellipses Pharma Limited
Websiteurl
ellipses.life
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Ellipses Pharma Limited is a UK-based, privately-held clinical-stage oncology drug development company founded in 2015 by Sir Christopher Evans and headquartered in London. The company specialises in acquiring rights to promising oncology candidates through licensing agreements and advancing them through clinical development, primarily in regions outside Greater China. Its portfolio is anchored by EP0031 (lunbotinib fumarate, also designated A400), a next-generation selective RET inhibitor licensed from Sichuan Kelun-Biotech in March 2021, which has demonstrated confirmed objective response rates of 87.1% in pre-treated and 81.3% in treatment-naïve RET fusion-positive NSCLC patients, alongside a 92.5% disease control rate in patients with CNS metastases. A second asset, EP0089 (GENA-104), is a CNTN4-targeting immuno-oncology antibody-drug conjugate licensed from Genome & Company that has entered a multi-country Phase 1/2a trial.

The company's core technology focus is targeted oncology therapeutics, with particular emphasis on next-generation RET inhibition and first-in-class ADC approaches. EP0031 is currently being advanced through FDA-cleared Phase II trials in the US, UK, Europe and the UAE. Ellipses Pharma generates revenue through licensing and development agreements that may include upfront fees, milestone payments, and royalties upon successful commercialisation by its partners; no products are approved and no commercial revenue is disclosed.

Ellipses Pharma is backed by Sir Tom Hunter's West Coast Capital, with a stated $150 million already invested into the pipeline and an additional $100 million planned. The company operates a capital-intensive, partnership-driven model in which the value-creation thesis rests on advancing a small number of high-conviction oncology assets through late-stage clinical development and monetising them via partnerships, milestones, or future out-licensing or M&A.

Short descriptiontext

Ellipses Pharma is a UK-based, privately-held clinical-stage oncology drug developer that licenses promising cancer therapies from biotech partners and advances them through Phase I/II trials, anchored by the RET inhibitor EP0031 and the ADC candidate EP0089.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, cancer therapeutics, targeted cancer therapy, antibody-drug conjugates, pharmaceutical licensing
Industry3 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Development Agreements
TypeLicensing Royalties
Description

Ellipses Pharma generates revenue through licensing deals where it acquires rights to promising oncology drug candidates and advances them through clinical development in specific geographic regions (typically outside Greater China), with potential milestone payments and royalties upon successful commercialization.

prnewswire.com
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ellipses Pharma is a clinical-stage oncology drug development company that acquires rights to promising cancer drug candidates from biotech partners and advances them through clinical trials for global (ex-Greater China) commercialization. Its core offerings are two in-licensed oncology drug candidates: EP0031, a next-generation selective RET inhibitor for RET fusion-positive NSCLC, and EP0089, a CNTN4-targeting immuno-oncology antibody-drug conjugate. Revenue is generated through licensing deals, milestone payments, and royalties on partnered candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 87.1% confirmed objective response rate in pre-treated RET fusion-positive NSCLC patients
+2 more records
Product overview1 text field

Ellipses Pharma is a UK-based cancer drug development company founded by Sir Christopher Evans. The company's core business is developing and licensing oncology drugs, with a focus on antibody-drug conjugates (ADCs) and targeted cancer therapies. Its portfolio includes EP0031 (lunbotinib fumarate), a next-generation RET inhibitor licensed from Kelun-Biotech for development outside Greater China, and EP0089, a CNTN4-targeting immuno-oncology candidate. Ellipses Pharma operates through strategic licensing partnerships, having invested $150 million in its pipeline with plans for additional investment.

Product and service2 records
1EP0031 (Lunbotinib Fumarate / A400)
CategoryOncology Drug Candidate — RET Inhibitor
Description

A next-generation selective RET inhibitor for RET fusion-positive non-small cell lung cancer (NSCLC), licensed from Kelun-Biotech. Demonstrated 87.1% confirmed objective response rate in pre-treated patients, 81.3% in treatment-naïve patients, and 92.5% disease control rate in patients with CNS metastases. Developed for global (ex-Greater China) markets through Phase II trials.

2EP0089 (GENA-104)
CategoryOncology Drug Candidate — Antibody-Drug Conjugate (ADC)
Description

A CNTN4-targeting immuno-oncology antibody-drug conjugate (ADC) candidate licensed from Genome & Company. Entering multi-country Phase 1/2a clinical trials as a first-in-class oncology candidate targeting the CNTN4 mechanism.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Kelun-Biotech licensed lunbotinib fumarate (A400/EP0031) to Ellipses Pharma for development outside Greater China in March 2021. EP0031 is a next-generation selective RET inhibitor demonstrating strong efficacy in RET fusion-positive NSCLC with 87.1% ORR in pre-treated patients. Ellipses Pharma is advancing the drug through Phase II trials in the US, UK, Europe and UAE.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Genome & Company partnered with Ellipses Pharma for the CNTN4-targeting immuno-oncology candidate GENA-104 (assigned code EP0089), which is entering a multi-country Phase 1/2a trial. This represents a strategic shift for Genome & Company toward first-in-class oncology drug development.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Nuvalent
TypeDirect peer
Description

Clinical-stage biotech developing next-generation selective kinase inhibitors for cancer, including a next-gen RET program (NVL-520). Directly comparable to Ellipses' EP0031 strategy of best-in-class targeted kinase inhibitors.

TypeDirect peer
Description

Markets GAVRETO (pralsetinib), an approved selective RET inhibitor for NSCLC, and develops precision oncology therapies. Direct incumbent competitor in the RET fusion-positive NSCLC space targeted by EP0031.

TypeDirect peer
Description

Designed next-generation kinase inhibitors for oncology (including repotrectinib for RET/ROS1/TRK), acquired by BMS for ~$4.1B. Highly comparable business model to Ellipses' targeted kinase inhibitor approach.

TypeDirect peer
Description

Clinical-stage precision oncology company developing allosteric kinase inhibitors. Comparable as a small-molecule targeted oncology developer with assets in early-to-mid stage clinical trials.

TypeDirect peer
Description

Clinical-stage oncology company developing targeted therapies against frontier cancer targets (RAS, etc.). Comparable stage, modality (targeted small molecules), and oncology focus.

TypeDirect peer
Description

Precision oncology company developing synthetic-lethality targeted therapies (SNP-focused discovery platform). Comparable clinical-stage profile and targeted oncology pipeline.

TypeDirect peer
Description

Clinical-stage precision oncology company focused on kinase inhibitors and targeted therapies. Comparable size, stage, and targeted-oncology therapeutic approach.

TypeBroad incumbent
Description

Developed targeted oncology therapies including KRAZATI (adagrasib), acquired by BMS for ~$4.8B. Comparable targeted oncology strategy at larger, more mature scale.

TypeOthers
Description

Chinese biotech that licensed EP0031 (lunbotinib) to Ellipses for development outside Greater China. A direct pipeline/licensing partner whose discovery productivity underpins Ellipses' lead asset.

TypeOthers
Description

Korean biotech that licensed CNTN4-targeting immuno-oncology candidate GENA-104 (EP0089) to Ellipses. A direct pipeline partner supplying Ellipses' second clinical asset and ADC exposure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ellipses Pharma

Oncology Pharmaceuticalsellipses.life

Ellipses Pharma is a UK-based, privately-held clinical-stage oncology drug developer that licenses promising cancer therapies from biotech partners and advances them through Phase I/II trials, anchored by the RET inhibitor EP0031 and the ADC candidate EP0089.

What Ellipses Pharma does

Ellipses Pharma Limited is a UK-based, privately-held clinical-stage oncology drug development company founded in 2015 by Sir Christopher Evans and headquartered in London. The company specialises in acquiring rights to promising oncology candidates through licensing agreements and advancing them through clinical development, primarily in regions outside Greater China. Its portfolio is anchored by EP0031 (lunbotinib fumarate, also designated A400), a next-generation selective RET inhibitor licensed from Sichuan Kelun-Biotech in March 2021, which has demonstrated confirmed objective response rates of 87.1% in pre-treated and 81.3% in treatment-naïve RET fusion-positive NSCLC patients, alongside a 92.5% disease control rate in patients with CNS metastases. A second asset, EP0089 (GENA-104), is a CNTN4-targeting immuno-oncology antibody-drug conjugate licensed from Genome & Company that has entered a multi-country Phase 1/2a trial.

The company's core technology focus is targeted oncology therapeutics, with particular emphasis on next-generation RET inhibition and first-in-class ADC approaches. EP0031 is currently being advanced through FDA-cleared Phase II trials in the US, UK, Europe and the UAE. Ellipses Pharma generates revenue through licensing and development agreements that may include upfront fees, milestone payments, and royalties upon successful commercialisation by its partners; no products are approved and no commercial revenue is disclosed.

Ellipses Pharma is backed by Sir Tom Hunter's West Coast Capital, with a stated $150 million already invested into the pipeline and an additional $100 million planned. The company operates a capital-intensive, partnership-driven model in which the value-creation thesis rests on advancing a small number of high-conviction oncology assets through late-stage clinical development and monetising them via partnerships, milestones, or future out-licensing or M&A.

Ellipses Pharma firmographics

Firmographics
Name
Ellipses Pharma
Legal name
Ellipses Pharma Limited
Website
https://ellipses.life
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Ellipses Pharma is a UK-based, privately-held clinical-stage oncology drug developer that licenses promising cancer therapies from biotech partners and advances them through Phase I/II trials, anchored by the RET inhibitor EP0031 and the ADC candidate EP0089.
Ownership category
akta.pro rank

Ellipses Pharma industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Oncology drug development
  • Cancer therapeutics
  • Targeted cancer therapy
  • Antibody-drug conjugates
  • Pharmaceutical licensing

Where Ellipses Pharma is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Ellipses Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Development Agreements: Ellipses Pharma generates revenue through licensing deals where it acquires rights to promising oncology drug candidates and advances them through clinical development in specific geographic regions (typically outside Greater China), with potential milestone payments and royalties upon successful commercialization.

Go-to-market motion1 record

Ellipses Pharma product offering

Product offering

Core offering

Ellipses Pharma is a clinical-stage oncology drug development company that acquires rights to promising cancer drug candidates from biotech partners and advances them through clinical trials for global (ex-Greater China) commercialization. Its core offerings are two in-licensed oncology drug candidates: EP0031, a next-generation selective RET inhibitor for RET fusion-positive NSCLC, and EP0089, a CNTN4-targeting immuno-oncology antibody-drug conjugate. Revenue is generated through licensing deals, milestone payments, and royalties on partnered candidates.

Product overview

Ellipses Pharma is a UK-based cancer drug development company founded by Sir Christopher Evans. The company's core business is developing and licensing oncology drugs, with a focus on antibody-drug conjugates (ADCs) and targeted cancer therapies. Its portfolio includes EP0031 (lunbotinib fumarate), a next-generation RET inhibitor licensed from Kelun-Biotech for development outside Greater China, and EP0089, a CNTN4-targeting immuno-oncology candidate. Ellipses Pharma operates through strategic licensing partnerships, having invested $150 million in its pipeline with plans for additional investment.

Differentiator

Problem solved

Functional benefit

Products and services

  • EP0031 (Lunbotinib Fumarate / A400) A next-generation selective RET inhibitor for RET fusion-positive non-small cell lung cancer (NSCLC), licensed from Kelun-Biotech. Demonstrated 87.1% confirmed objective response rate in pre-treated patients, 81.3% in treatment-naïve patients, and 92.5% disease control rate in patients with CNS metastases. Developed for global (ex-Greater China) markets through Phase II trials.
  • EP0089 (GENA-104) A CNTN4-targeting immuno-oncology antibody-drug conjugate (ADC) candidate licensed from Genome & Company. Entering multi-country Phase 1/2a clinical trials as a first-in-class oncology candidate targeting the CNTN4 mechanism.

Quantifiable outcome

  • 87.1% confirmed objective response rate in pre-treated RET fusion-positive NSCLC patients
  • +2 more outcomes

Companies that use Ellipses Pharma

Customer profile

Segments1 record

Ideal customer profiles2 records

Ellipses Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Ellipses Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Kelun-BiotechcoreStrategic or Co-development Partner · 1 March 2021Kelun-Biotech licensed lunbotinib fumarate (A400/EP0031) to Ellipses Pharma for development outside Greater China in March 2021. EP0031 is a next-generation selective RET inhibitor demonstrating strong efficacy in RET fusion-positive NSCLC with 87.1% ORR in pre-treated patients. Ellipses Pharma is advancing the drug through Phase II trials in the US, UK, Europe and UAE.
  • Genome & CompanycoreStrategic or Co-development PartnerGenome & Company partnered with Ellipses Pharma for the CNTN4-targeting immuno-oncology candidate GENA-104 (assigned code EP0089), which is entering a multi-country Phase 1/2a trial. This represents a strategic shift for Genome & Company toward first-in-class oncology drug development.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Ellipses Pharma competitors and assessment

Company assessment

Direct peers

  • Nuvalent: Clinical-stage biotech developing next-generation selective kinase inhibitors for cancer, including a next-gen RET program (NVL-520). Directly comparable to Ellipses' EP0031 strategy of best-in-class targeted kinase inhibitors.
  • Blueprint Medicines: Markets GAVRETO (pralsetinib), an approved selective RET inhibitor for NSCLC, and develops precision oncology therapies. Direct incumbent competitor in the RET fusion-positive NSCLC space targeted by EP0031.
  • Turning Point Therapeutics: Designed next-generation kinase inhibitors for oncology (including repotrectinib for RET/ROS1/TRK), acquired by BMS for ~$4.1B. Highly comparable business model to Ellipses' targeted kinase inhibitor approach.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric kinase inhibitors. Comparable as a small-molecule targeted oncology developer with assets in early-to-mid stage clinical trials.
  • Revolution Medicines: Clinical-stage oncology company developing targeted therapies against frontier cancer targets (RAS, etc.). Comparable stage, modality (targeted small molecules), and oncology focus.
  • Repare Therapeutics: Precision oncology company developing synthetic-lethality targeted therapies (SNP-focused discovery platform). Comparable clinical-stage profile and targeted oncology pipeline.
  • Cogent Biosciences: Clinical-stage precision oncology company focused on kinase inhibitors and targeted therapies. Comparable size, stage, and targeted-oncology therapeutic approach.

Broad incumbents

  • Mirati Therapeutics: Developed targeted oncology therapies including KRAZATI (adagrasib), acquired by BMS for ~$4.8B. Comparable targeted oncology strategy at larger, more mature scale.

Others

  • Kelun-Biotech: Chinese biotech that licensed EP0031 (lunbotinib) to Ellipses for development outside Greater China. A direct pipeline/licensing partner whose discovery productivity underpins Ellipses' lead asset.
  • Genome & Company: Korean biotech that licensed CNTN4-targeting immuno-oncology candidate GENA-104 (EP0089) to Ellipses. A direct pipeline partner supplying Ellipses' second clinical asset and ADC exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Ellipses Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ellipses Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Ellipses Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ellipses Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ellipses Pharma

What does Ellipses Pharma do?

Ellipses Pharma is a clinical-stage oncology drug development company that acquires rights to promising cancer drug candidates from biotech partners and advances them through clinical trials for global (ex-Greater China) commercialization. Its core offerings are two in-licensed oncology drug candidates: EP0031, a next-generation selective RET inhibitor for RET fusion-positive NSCLC, and EP0089, a CNTN4-targeting immuno-oncology antibody-drug conjugate. Revenue is generated through licensing deals, milestone payments, and royalties on partnered candidates.

Is Ellipses Pharma a public or private company?

Ellipses Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ellipses Pharma founded?

Ellipses Pharma was founded in 2015. It employs 11 to 50 people.

Where is Ellipses Pharma based?

Ellipses Pharma is headquartered in London, United Kingdom, in the Europe region.

How does Ellipses Pharma make money?

One revenue line is on record: licensing and Development Agreements.

Who are Ellipses Pharma's main competitors?

Direct peers on record are Nuvalent, Blueprint Medicines, Turning Point Therapeutics, Black Diamond Therapeutics, Revolution Medicines, Repare Therapeutics and Cogent Biosciences. Mirati Therapeutics is listed as a broad incumbent. Others are Kelun-Biotech and Genome & Company.

Does Ellipses Pharma have an API?

No public API is recorded for Ellipses Pharma.

What industry is Ellipses Pharma in?

Ellipses Pharma's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate英 엘립시스 파마, 증시 상장 추진…지놈앤컴퍼니 기술이전 'EP0089' 주목 : 네이트 뉴스Ellipses Pharma, a UK cancer drug developer, signed a non-binding MOU with Wolfram Resources for a reverse merger to list on the London Stock Exchange. The deal targets completion in early 2027, with a rights issue planned. The company will use public funds to accelerate its pipeline, including the Genmab-transferred EP0089.Naver英 엘립시스 파마, 증시 상장 추진…지놈앤컴퍼니 기술이전 'EP0089' 주목Ellipses Pharma, a UK cancer drug developer, plans to list on the London Stock Exchange via a reverse merger with Wolfram Resources. The company acquired Genmab's EP0089 immunotherapy candidate and aims to complete the deal by early 2027. The listing is expected to boost funding for EP0089's development.Pharmaceutical TechnologyEllipses Pharma plots London listing that could end British biotech IPO drought - Pharmaceutical TechnologyEllipses Pharma, a London-based cancer drug developer, signed an agreement in principle with SPAC Wolfram Resources for a potential London IPO. The deal targets completion by early 2027, though no guarantee is given. This could end a dry spell for British biotech listings, as none listed on the LSE in 2026.The Pharma LetterEllipses eyes London main market listing through reverse takeover of shell company WolframEllipses Pharma is exploring a London Stock Exchange main market listing via a reverse takeover of Wolfram Resources, a listed SPAC. The company signed a non-binding memorandum of understanding under which Wolfram would acquire Ellipses' entire issued share capital, with the enlarged group re-listing in the commercial companies category.Nate영국 항암제 개발사 엘립시스파마, 런던증시 상장 추진…2027년 초 완료 목표 : 네이트 뉴스Ellipses Pharma, a UK cancer drug developer, is pursuing a London Stock Exchange listing via a reverse merger with SPAC Wolfram Resources, targeting completion in early 2027. The deal would allow the company to raise capital for its oncology pipeline, including EP0031 and EP0062, though final terms remain undisclosed.Business LiveCelebrity-backed Ellipses Pharma targets £450m London listingEllipses Pharma, a cancer drug venture founded by Sir Chris Evans, is preparing to float on the London Stock Exchange via a reverse takeover, targeting a valuation of £450m-£500m. Abu Dhabi's sovereign wealth fund Mubadala holds a 45% stake, and the company has invested about £185m in its pipeline. A formal announcement could come as early as this week.CityAMCelebrity-backed cancer treatment venture eyes London listingEllipses Pharma, a celebrity-backed cancer treatment venture, is planning a London Stock Exchange listing via reverse takeover of Wolfram Resources. The company, backed by Abu Dhabi's sovereign wealth fund with a 45% stake, targets a valuation of £450m–£500m. It has invested about £185m in its drug pipeline.Laotian TimesKelun-Biotech Announces 2026 Interim ResultsKelun-Biotech reported a 112% year-over-year increase in pharmaceutical sales revenue to RMB 657 million for the first half of 2026, driven by the inclusion of its products in China's National Reimbursement Drug List and strong clinical data recognition. The company is advancing its global expansion through strategic collaborations with partners including Merck Sharp & Dohme (MSD) for sac-TMT trials, Ellipses Pharma for Lunbotinib development, and Windward Bio for respiratory disease assets.